EUVIMEDEUVIMED entdecken
Crossref

Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo

Xuewen Zhang, Lirong Zhang, Zhiqiang Sun, Chenglong Xu, Jiamin Tan, Yichang Ren, Jian Zhang, Ting Chen, Zhijie Wang, Dulin Kong, Jianjun Chen

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.109477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Xuewen Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutic…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Antineoplastic Agents, Indoles, Pyridines. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Southern Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To broaden the structural diversity of contemporary small molecule PD-L1 inhibitors, we rationally designed and synthesized a novel series of PD-L1 targeting compounds based on the structural features of the known lead compound 24, incorporating indole and pyrrolopyridine scaffolds. Among these, compound Z38 emerged as the most potent candidate, with a half maximal inhibitory concentration (IC₅₀) of 110 nM against PD-L1 and significantly lower cytotoxicity than the lead compound. Z38 exerted dose dependent immunomodulatory effects in a HepG2/Jurkat T cell coculture system, promoting HepG2 cell death by restoring T cell mediated antitumor immunity. In B16-F10 melanoma bearing mice, intraperitoneal administration of Z38 (30 mg/kg) achieved a tumor growth inhibition rate (TGI) of 60 % without detectable organ toxicity. Mechanistically, Z38 activated the tumor immune microenvironment by increasing tumor infiltrating lymphocytes (TILs) and inducing ∼50 % PD-L1 degradation in tumor tissues. This work identifies Z38 as a structurally distinct, low toxicity PD-L1 inhibitor with robust in vitro and in vivo antitumor efficacy, offering a promising lead for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenAntineoplastic AgentsIndolesPyridinesPyrrolesDrug DiscoveryImmune Checkpoint InhibitorsHumansAnimalsMiceStructure-Activity RelationshipMolecular StructureMice, Inbred C57BLDose-Response Relationship, DrugDrug Screening Assays, AntitumorCell ProliferationMelanoma, Experimental

Stichwörter der Autor:innen

ImmunotherapyPD-1/PD-L1 inhibitorsPyrrolopyridine

Substanzen

B7-H1 AntigenAntineoplastic AgentsIndolesPyridinesPyrrolesCD274 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • The Seventh Affiliated Hospital, Southern Medical University, Foshan 528244, China.
  • Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Dep…
  • Department of Stomatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: 252199453@qq.com.
  • Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China. Electronic address: wzj95cpu@163.com.
  • Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, International Joint Research Center of Human-Machine Intelligent Collaborative for Tumor Precision Diagnosis and T…

Förderung

  • Southern Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., Zhang, L., Sun, Z., Xu, C., Tan, J., Ren, Y., Zhang, J., Chen, T., Wang, Z., Kong, D., & Chen, J. (2026). Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109477

Vancouver

Zhang X, Zhang L, Sun Z, Xu C, Tan J, Ren Y, et al. Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109477

BibTeX
@article{Zhang2026,
  author = {Zhang, Xuewen and Zhang, Lirong and Sun, Zhiqiang and Xu, Chenglong and Tan, Jiamin and Ren, Yichang and Zhang, Jian and Chen, Ting and Wang, Zhijie and Kong, Dulin and Chen, Jianjun},
  title = {Discovery of PD-L1 inhibitors featuring novel indole and pyrrolopyridine scaffolds with PD-L1 degradation activity in vivo},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.109477}
}
Kostenlos starten →